Maintenance chemo after chemoradiation for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a maintenance chemotherapy drug called S-1 given after standard chemoradiation for locally advanced esophageal cancer. It may help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 20 years old.
- You have been diagnosed with a type of esophageal cancer (squamous cell, adenocarcinoma, or gastroesophageal junction cancer).
- Your cancer is stage II to IVA and cannot be removed with surgery (or you choose not to have surgery).
- You have received standard chemoradiation (chemo with a platinum drug and radiation) and your scans show the cancer did not get worse.
- Your overall health is good enough for chemo (adequate organ function, able to do daily activities).
- You have not had another cancer in the last 2 years (except esophageal cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding radiation therapy after initial chemoimmunotherapy improves outcomes for people with locally advanced esophageal cancer. It is designed for patients whose tumors are still responding or stable after the first treatment.
This trial tests if adding radiation before and after standard chemotherapy can help people whose esophageal cancer has come back after initial treatment. It aims to improve control of the cancer while keeping side effects manageable.
This trial compares two approaches for people with esophageal cancer that has shrunk or disappeared after initial chemotherapy combined with immunotherapy. It looks at whether adding targeted radiation (DCRT) or surgery is better. The goal is to find the most effective next step for eligible patients.
This trial tests a treatment for locally advanced esophageal cancer. You'll receive chemoradiation (chemo plus radiation) followed by a maintenance drug (a PD-1 inhibitor) to help prevent the cancer from coming back.
This Phase 2 study tests whether adding tislelizumab (an immunotherapy drug) to chemotherapy before a combined course of chemotherapy and radiation can better treat locally advanced, non-surgable esophageal squamous cell cancer. It’s for adults who cannot have surgery and may help shrink the cancer and improve control of the disease.
This trial tests whether adding immunotherapy to standard chemoradiation (chemotherapy plus radiation) can help preserve the esophagus and avoid surgery in people with resectable esophageal cancer. It aims to see if this combination is safer and more effective than current treatment.
Hear when a new Locally Advanced Unresectable Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.